Psoriatic arthritis.

Dafna D Gladman

Journal: Dermatologic therapy 2005;17(5):350-63

PMID: 15379770

Full Text on Ovid Technologies, Inc. View on PubMed

Abstract

Although there is still some controversy about the existence of psoriatic arthritis as a specific form of inflammatory arthritis associated with psoriasis, epidemiological, and clinical studies support the unique features of psoriatic arthritis. Because of lack of diagnostic or classification criteria, the disease has been thought of as uncommon. Over the past several decades, it has become clear that the disease leads to serious disability and even increased mortality. Traditional medications have not been effective in preventing the progression of joint damage. New medications, including biologics, have emerged with the potential to control the inflammation and arrest the progression of joint damage.

Address: Center for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, Toronto, Ontario. [email protected]

DOI: 10.1111/j.1396-0296.2004.04038.x

Link outs

Free resources

Medical:

https://medlineplus.gov/psoriaticarthritis.html

Miscellaneous:

https://assays.cancer.gov/CPTAC-68

Subscription / membership required

Full Text Sources:

MeSH Terms: Adalimumab, Alefacept, Anti-Inflammatory Agents, Non-Steroidal, Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antimalarials, Arthritis, Psoriatic, Azathioprine, Cyclosporine, Etanercept, Gold Sodium Thiomalate, Humans, Immunoglobulin G, Infliximab, Isoxazoles, Leflunomide, Receptors, Tumor Necrosis Factor, Receptors, Tumor Necrosis Factor, Type I, Recombinant Fusion Proteins, Sulfasalazine, Tumor Necrosis Factor Decoy Receptors